Oral Anti̇aggregant Agents in Cardi̇ology
Özet
Referanslar
Cadavid AP. Aspirin: The mechanism of action revisited in thecontext of pregnancy complications. Front. Immunol. 2017; 8: 261. doi: 10.3389/fimmu.2017.00261
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231(25):232–235. doi:10.1038/ newbio231232a0
Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231(25):235–237. doi:10.1038/ newbio231235a0
Awtry EH, Loscalzo J. Cardiovascular Drugs: Aspirin. Circulation. 2000; 101: 1206-1218.
Latini R, Cerletti C, de Gaetano G et al. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Int J Clin Pharmacol Ther Toxicol. 1986; 24: 313–318.
Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthase by oral aspirin. J Clin Invest. 1979; 61: 314-319.
Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985; 72: 177–184.
Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2synthase. Nat Struct Biol. 1995; 2: 637– 643.
McNeil JJ, Wolfe R, Woods RL et al. ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379: 1509 –1518. doi:10.1056/NEJMoa1805819
Gaziano JM, Brotons C, Coppolecchia R, et al. ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in pa- tients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–1046. doi: 10.1016/S0140-6736(18)31924-X
Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary pre- vention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529 – 1539. doi: 10.1056/NEJMoa1804988
Berger JS. Aspirin for primary prevention- Time to rethink our approach. JAMA Network Open. 2022; 5(4):e2210144. doi:10.1001/jamanetworkopen.2022.10144
Arnett DK,Blumenthal RS, Albert MA,et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11): e596-e646. doi:10.1161/CIR.0000000000000678
Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-3337. doi: 10.1093/eurheartj/ehab484
Davidson KW, Mangione CM, Barry MJ, etal. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. Published online April 26, 2022.doi:10.1001/jama. 2022.4983
Antiplatelet Trialists’ Collaboration. Secondary prevention of vascu- lar disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed). 1988;296:320–331.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of pa- tients. BMJ. 1994;308:81–106.
Jakobsen AP, Raber I, Blumenthal RS et al. Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome. Circulation. 2020; 142: 1579–1590. Doi:10.1161/CIRCULATIONAHA.120.045695
Collet JP, Thiele H, Barbato E et al. 2020 ESC Guidelines fort he management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal (2021) 42, 1289-1367. doi:10.1093/eurheartj/ehaa575
Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines fort he diagnosis and management of chronic coronary syndromes. European Heart Journal (2020) 41, 407-477 doi:10.1093/eurheartj/ehz425
Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal (2009) 30, 1964–1977 doi:10.1093/eurheartj/ehp296
Cattaneo M. Update on antithrombotic therapy: New P2Y12 inhibitors. Circulation. 2010; 121: 171-179. Doi:10.1161/CIRCULATIONAHA.109.853069
Damman P, Woudstra P, Kuljt W et al. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 33:143–153 DOI 10.1007/s11239-011-0667-5
Pocock SJ, Mehran R, Clayton TC et al (2010) Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy Trial. Circulation 121(1):43–51
Vaglimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal (2018) 39, 213–254 doi:10.1093/eurheartj/ehx419
Referanslar
Cadavid AP. Aspirin: The mechanism of action revisited in thecontext of pregnancy complications. Front. Immunol. 2017; 8: 261. doi: 10.3389/fimmu.2017.00261
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231(25):232–235. doi:10.1038/ newbio231232a0
Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231(25):235–237. doi:10.1038/ newbio231235a0
Awtry EH, Loscalzo J. Cardiovascular Drugs: Aspirin. Circulation. 2000; 101: 1206-1218.
Latini R, Cerletti C, de Gaetano G et al. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Int J Clin Pharmacol Ther Toxicol. 1986; 24: 313–318.
Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthase by oral aspirin. J Clin Invest. 1979; 61: 314-319.
Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985; 72: 177–184.
Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2synthase. Nat Struct Biol. 1995; 2: 637– 643.
McNeil JJ, Wolfe R, Woods RL et al. ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379: 1509 –1518. doi:10.1056/NEJMoa1805819
Gaziano JM, Brotons C, Coppolecchia R, et al. ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in pa- tients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–1046. doi: 10.1016/S0140-6736(18)31924-X
Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary pre- vention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529 – 1539. doi: 10.1056/NEJMoa1804988
Berger JS. Aspirin for primary prevention- Time to rethink our approach. JAMA Network Open. 2022; 5(4):e2210144. doi:10.1001/jamanetworkopen.2022.10144
Arnett DK,Blumenthal RS, Albert MA,et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11): e596-e646. doi:10.1161/CIR.0000000000000678
Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-3337. doi: 10.1093/eurheartj/ehab484
Davidson KW, Mangione CM, Barry MJ, etal. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. Published online April 26, 2022.doi:10.1001/jama. 2022.4983
Antiplatelet Trialists’ Collaboration. Secondary prevention of vascu- lar disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed). 1988;296:320–331.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of pa- tients. BMJ. 1994;308:81–106.
Jakobsen AP, Raber I, Blumenthal RS et al. Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome. Circulation. 2020; 142: 1579–1590. Doi:10.1161/CIRCULATIONAHA.120.045695
Collet JP, Thiele H, Barbato E et al. 2020 ESC Guidelines fort he management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal (2021) 42, 1289-1367. doi:10.1093/eurheartj/ehaa575
Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines fort he diagnosis and management of chronic coronary syndromes. European Heart Journal (2020) 41, 407-477 doi:10.1093/eurheartj/ehz425
Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal (2009) 30, 1964–1977 doi:10.1093/eurheartj/ehp296
Cattaneo M. Update on antithrombotic therapy: New P2Y12 inhibitors. Circulation. 2010; 121: 171-179. Doi:10.1161/CIRCULATIONAHA.109.853069
Damman P, Woudstra P, Kuljt W et al. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 33:143–153 DOI 10.1007/s11239-011-0667-5
Pocock SJ, Mehran R, Clayton TC et al (2010) Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy Trial. Circulation 121(1):43–51
Vaglimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal (2018) 39, 213–254 doi:10.1093/eurheartj/ehx419
